RMEBX
Price
$64.44
Change
+$0.03 (+0.05%)
Updated
Jul 31 closing price
Net Assets
118.05B
STVTX
Price
$11.12
Change
+$0.07 (+0.63%)
Updated
Jul 31 closing price
Net Assets
275.18M
Interact to see
Advertisement

RMEBX vs STVTX

RMEBX vs STVTX Comparison Chart in %
View a ticker or compare two or three
VS
RMEBX vs. STVTX commentary
Aug 03, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RMEBX is a Buy and STVTX is a Buy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
RMEBX has more cash in the bank: 118B vs. STVTX (275M). STVTX pays higher dividends than RMEBX: STVTX (1.23) vs RMEBX (0.99). RMEBX was incepted earlier than STVTX: RMEBX (12 years) vs STVTX (33 years). STVTX (1.08) and RMEBX (1.07) have similar cost to investors . STVTX is a more actively managed with annual turnover of: 157.00 vs. RMEBX (30.00). RMEBX has a lower initial minimum investment than STVTX: RMEBX (250) vs STVTX (100000). STVTX annual gain was more profitable for investors over the last year : 9.51 vs. RMEBX (8.96). RMEBX return over 5 years is better than : 36.13 vs. STVTX (-23.51).
RMEBXSTVTXRMEBX / STVTX
Total Expense Ratio1.070.89120%
Annual Report Gross Expense Ratio1.071.0899%
Fund Existence12 years33 years-
Gain YTD9.41614.87663%
Front LoadN/AN/A-
Min. Initial Investment2501000000%
Min. Initial Investment IRAN/AN/A-
Net Assets118B275M42,909%
Annual Yield % from dividends0.991.2381%
Returns for 1 year8.969.5194%
Returns for 3 years32.638.51383%
Returns for 5 years36.13-23.51-154%
Returns for 10 years90.64-19.68-461%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
IEOTX15.100.17
+1.14%
Voya Large Cap Growth Port S2
JRAAX88.86N/A
N/A
Janus Henderson Research A
VLLIX45.39-0.03
-0.07%
Value Line Larger Companies Focus Instl
BHCFX21.68-0.10
-0.46%
Baron Health Care Retail
FBDIX193.96-3.99
-2.02%
Franklin Biotechnology Discovery A